Analyst Upgrades

• Xilinx (XLNX) to buy from hold at Auriga.
• Orion Energy (OESX) to buy from neutral at Roth Capital.
• Goodyear Tire (GT) to buy from fair value at CRT Capital.
• RadioShack (RSH) to neutral from underperform at Wedbush.
• Novo Nordisk (NVO) to buy from neutral at Goldman.

Continue reading Analyst Calls: ADBE, CE, CISG, DOW, ELN, GT, NSC, NVO, RSH, XLNX ...

Analyst Calls: ADBE, CE, CISG, DOW, ELN, GT, NSC, NVO, RSH, XLNX ... originally appeared on BloggingStocks on Tue, 25 Jan 2011 12:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• NYSE Euronex (NYX) to conviction buy from neutral at Goldman.
• General Dynamics (GD) to buy from hold at Citigroup.
• Deere (DE), Parker-Hannifin (PH) and ExlService (EXLS) to overweight from neutral at JPMorgan.
• Aflac (AFL) to outperform from market perform at FBR Capital.
• Wynn Resorts (WYNN) to buy from neutral at Janney Capital.
• Amdocs (DOX) to buy from neutral at UBS.
• Juniper (JNPR) to buy from hold at ThinkEquity.
• Rudolph Tech (RTEC) and KLA-Tencor (KLAC) to perform from underperform at Oppenheimer.
• Hershey (HSY) and Pinnacle Entertainment (PNK) to outperform from market perform at Wells Fargo.
• Spirit AeroSystems (SPR) to equal weight from underweight at Morgan Stanley.
• Micron (MU) to outperform from neutral at RW Baird.

Continue reading Analyst Calls: AFL, DE, DOX, GD, GS, HSY, ITT, MS, NYX, TXN, UBS, WYNN ...

Analyst Calls: AFL, DE, DOX, GD, GS, HSY, ITT, MS, NYX, TXN, UBS, WYNN ... originally appeared on BloggingStocks on Thu, 13 Jan 2011 11:40:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Cisco (CSCO) to outperform from perform at Oppenheimer.
• Cognizant (CTSH) to buy from neutral at Goldman.
• Polypore (PPO) to outperform from neutral at RW Baird.
• Elan (ELN) to buy from neutral at UBS.
• Millicom (MICC) and NuStar GP Holdings (NSH) to overweight from equal weight at Morgan Stanley.
• Teekay LNG (TGP) to equal weight from underweight at Morgan Stanley.
• American Railcar (ARII) to outperform from market perform at Morgan Keegan.
• Texas Instruments (TXN) to buy from neutral at Sterne Agee.

Continue reading Analyst Calls: ARO, CSCO, CTSH, ELN, EZCH, LEAP, OGE, TXN, WIN ...

Analyst Calls: ARO, CSCO, CTSH, ELN, EZCH, LEAP, OGE, TXN, WIN ... originally appeared on BloggingStocks on Mon, 06 Dec 2010 10:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Goldman upgraded BP (BP) to buy from neutral.
• STEC (STEC) was upgraded to buy from hold at Needham.
• MCG Capital (MCGC) was upgraded to buy from hold at BB&T.
• Corporate Office (OFC) was upgraded to market perform from underperform at FBR Capital.
• Citigroup upgraded K-Sea Transportation (KSP) and Post Properties (PPS) to hold from sell.
• BofA/Merrill upgraded Embraer (ERJ) to buy from underperform.
• Wilmington Trust (WL) was upgraded to neutral from underperform at Macquarie.
• Parkway Properties (PKY) was upgraded to hold from sell at Stifel Nicolaus.

Continue reading Analyst Calls: BP, EOG, FDO, MOT, MRO, NEM, NOK, ODP, RIMM, TGB ...

Analyst Calls: BP, EOG, FDO, MOT, MRO, NEM, NOK, ODP, RIMM, TGB ... originally appeared on BloggingStocks on Wed, 03 Nov 2010 11:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Citigroup upgraded Baker Hughes (BHI) to hold from sell following the company's Q1 results.
• Auriga upgraded Canadian Solar (CSIQ) to buy from hold as it believes the company's negative preannouncement on April 20 removes a downside catalyst. Despite upgrading, the firm lowered its target for shares to $21 from $25.
• Deutsche Bank upgraded Post Properties (PPS) to hold from sell following the company's Q1 results. The firm upped its target for shares to $27 from $16.
• Wright Express (WXS) was upgraded to buy from neutral at Goldman.
• Nvidia (NVDA) coverage was assumed with a buy from hold at ThinkEquity.
• Elan (ELN) was upgraded to neutral from sell at UBS.

Continue reading Analyst Calls: AMD, BHI, CSIQ, INTC, ITMN, MRK, MYGN, PPS, TXN ...

Analyst Calls: AMD, BHI, CSIQ, INTC, ITMN, MRK, MYGN, PPS, TXN ... originally appeared on BloggingStocks on Wed, 05 May 2010 11:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Citigroup upgraded Blackrock (BLK) to hold from sell and removed the stock from its Top Picks Live list as a sell. The firm upped its target for shares to $198 from $190.
• Jesup & Lamont upgraded Starbucks (SBUX) to buy from hold following the company's Q2 results. The firm raised its target for shares to $32 from $25.
• CLSA upgraded Nabors Industries (NBR) to outperform from underperform. The firm said the Q1 report was in-line with their estimate and they expect U.S. land drilling to continue to improve. The firm has a $24 price target on the stock.
• Alcoa (AA) was upgraded to neutral from underweight at HSBC.
• Boeing (BA) was upgraded to outperform from neutral at Credit Suisse.
• Chipotle Mexican Grill (CMG) was upgraded to buy from hold at Jefferies.

Continue reading Analyst Calls: AA, BA, BLK, DCTH, EBAY, NBR, SBUX, STI, TWX ...

Analyst Calls: AA, BA, BLK, DCTH, EBAY, NBR, SBUX, STI, TWX ... originally appeared on BloggingStocks on Thu, 22 Apr 2010 11:40:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Jefferies upgraded St. Jude (STJ) to buy from hold and raised its target to $49 from $39. The firm cites valuation and the positive impact from the Boston Scientific (BSX) ICD recall for the upgrade. Shares were also upgraded to neutral from sell at Goldman, as the firm sees upside for shares into Q1 results.
• RBC Capital upgraded EMC Corp. (EMC) to outperform from sector perform and raised its target to $22 from $21. The firm upgraded shares based on valuation and believes the company can meet or modestly beat March quarter expectations.
• Auriga upgraded MetroPCS (PCS) to buy from hold as it believes customer migration away from postpaid to prepaid may be accelerating. The firm raised its target for shares to $9 from $7.
• Caterpillar (CAT) was raised to outperform from neutral at Baird.
• Best Buy (BBY) was upgraded to market perform from underperform at FBR Capital.
• Expedia (EXPE) was upgraded to overweight from neutral at Piper Jaffray.

Continue reading Analyst Calls: BBY, CAT, EMC, EXPE, FCX, ICE, NTAP, PCE, STJ, VRTX ...

Analyst Calls: BBY, CAT, EMC, EXPE, FCX, ICE, NTAP, PCE, STJ, VRTX ... originally appeared on BloggingStocks on Mon, 12 Apr 2010 11:10:00 EST. Please see our terms for use of feeds.

During 2009, drug treatments for ten diseases in the U.S. will bring pharma companies nearly $170 billion in sales. Those include drugs for major killers like cardiovascular diseases and a number of cancers. Also among the most successful emerging treatments are ones for mental disorders.

Patents on a number of the older blockbuster drugs are running out and a new generation of biotech drugs is offering competition to traditional treatments. Some of the companies that are in the next wave of solving medicine's largest problems are worth watching.

Continue reading Finding biotech's big winners

Finding biotech's big winners originally appeared on BloggingStocks on Wed, 22 Jul 2009 11:00:00 EST. Please see our terms for use of feeds.

• Citigroup upgraded Allergan (NYSE: AGN) to Buy from Hold to reflect increased estimates for Botox and its belief Latisse guidance looks conservative. The firm raised its target on shares to $57 from $45.
  
• Jefferies upgraded Texas Instruments (TXN) to Hold from Underperform after channel checks indicated business is strengthening. Jefferies believes Texas Instruments' September quarter guidance will come in better than expected and raised its target on shares to 23 from $16.
  
• FBR Capital upgraded Peabody Energy (BTU) to Outperform from Market Perform to reflect "strong" long-term steel and steam demand trends from China and India. The firm raised its target on shares to $44 from $36.
  
• Elan Corp (ELN) was upgraded to Buy from Neutral at UBS.
  
• Affymetrix (AFFX) was upgraded to Equal Weight from Underweight at Morgan Stanley.
  
• ASML Holding (ASML) was upgraded to Buy from Neutral at BofA/Merrill.

Continue reading Analyst upgrades, downgrades and initiations: AGN, TXN, ELN, PALM, DOW

Analyst upgrades, downgrades and initiations: AGN, TXN, ELN, PALM, DOW originally appeared on BloggingStocks on Mon, 20 Jul 2009 12:00:00 EST. Please see our terms for use of feeds.

Continue reading Elan (ELN) drops on Tysabri troubles

Elan (ELN) drops on Tysabri troubles originally appeared on BloggingStocks on Mon, 29 Jun 2009 13:30:00 EST. Please see our terms for use of feeds.

Continue reading Elan: Yet another deal rumor -- Bristol eyeing a stake

Elan: Yet another deal rumor -- Bristol eyeing a stake originally appeared on BloggingStocks on Mon, 01 Jun 2009 13:50:00 EST. Please see our terms for use of feeds.

• Goldman upgraded Intercontinental Exchange (NYSE: ICE) to Conviction Buy from Neutral and raised their target to $90 from $60. Goldman cites ICE's positioning and potential for upward EPS revisions for the upgrade.
  
• Jefferies upgraded FMC Technologies (NYSE: FTI) to Buy from Hold as they believe solid deepwater activity levels will lead to solid EPS results in 2009 and 2010. The firm raised their price target to $45 from $27.
  
• Friedman Billings upgraded Devon Energy (NYSE: DVN) to Outperform from Market Perform on valuation and expects significant improvement in basis differentials for the company's Barnett production starting the second half of Q2. The firm raised their price target to $60 from $50.
• Elan Corp (NYSE: ELN) was raised to Neutral from Sell at Piper Jaffray.
  
• Banco Santander (NYSE: STD) was upgraded at Keefe Bruyette to Outperform from Market Perform.

Continue reading Analyst upgrades, downgrades and initiations: ICE, AKAM, WFMI, GD, INTU ...

Analyst upgrades, downgrades and initiations: ICE, AKAM, WFMI, GD, INTU ... originally appeared on BloggingStocks on Fri, 03 Apr 2009 12:10:00 EST. Please see our terms for use of feeds.

• Thomas Weisel upgraded SanDisk (NASDAQ:SNDK) to Market Weight from Underweight. Thomas Weisel said they are less negative on the outlook for memory industry dynamics but they do expect SanDisk shares to be range bound.
  
• Citigroup upgraded shares of Hershey (NYSE:HSY) to Buy from Hold as they believe Hershey is benefiting from increased advertising spending and the consumer trade-down to less expensive chocolate. The firm maintains a $39 target on the stock.
  
• Deutsche Bank upgraded Best Buy (NYSE:BBY) to Buy from Holdas they believe the company will be a beneficiary from the Circuit City liquidation.
• Ericsson (NASDAQ:ERIC) was upgraded to Neutral from Sell at Goldman.
  
• Advance Auto Parts (NYSE:AAP) and Virgin Media (NASDAQ:VMED) were raised to Overweight from Neutral at JP Morgan.
  
• NewMarket (NYSE:NEU) was upgraded at KeyBanc to Buy from Hold.

• Citigroup downgraded Kellogg (NYSE:K) to Hold from Buy as they believe the company's U.S. trends are decelerating and that FX trends will have a negative impact. The firm lowered their target price to $47 from $58.
  
• Jefferies downgraded Cerner (NASDAQ:CERN) to Hold from Buy following Eclipsys' (NASDAQ:ECLP) negative pre-announcement as they believe both companies are suffering from a downturn in hospital spending. Jefferies lowered their target on Cerner to $38 from $51.
  
• Oppenheimer cut Amdocs (DOX) to Perform from Outperform following the weak Q1 results citing lack of near-term catalysts and the macroeconomic slowdown.
• Eclipsys (NASDAQ:ECLP)was downgraded to Underperform from Buy at Jefferies and to Neutral from Buy at Piper Jaffray.
  
• PetSmart (NASDAQ:PETM) was downgraded to Hold from Buy at Deutsche Bank.
  
• Fulton Financial (NASDAQ:FULT) was lowered to Underperform from Market Perform at Keefe Bruyette.

• Wunderlich initiated Republic Services (NYSE:RSG) with a Buy rating and $30 target and believes the company should enjoy sustainable pricing leverage following the merger with Waste Management.
  
• RBC Capital initiated Elan Corp (NYSE:ELN) with an Underperform rating and $4 target based on Tysabri uncertainty, bapineuzumab clinical risk, MS competition, and debt overhang.
  
• Oppenheimer expects Ligand Pharmaceuticals (NASDAQ:LGND) to become an aggressive acquirer of financially distressed biotech companies with the completion of the acquisition of Pharmacopeia. Shares were assumed with an Outperform rating and $5 target.
• Zebra Tech (NASDAQ:ZBRA) was initiated with a Neutral rating and $25 target at JP Morgan.
  
• Activision (NASDAQ:ATVI) was reinitiated at Friedman Billings with an Outperform rating and $14 target.
  
• Ameren (NYSE:AEE) was assumed with a Hold rating at Jesup & Lamont.

Analyst upgrades, downgrades and initiations: BBY, K, SNDK, H, ERIC originally appeared on BloggingStocks on Thu, 22 Jan 2009 11:44:00 EST. Please see our terms for use of feeds.

Elan (NYSE: ELN) said it is initiating a strategic review which could result in a minority investment, a strategic alliance, a merger, or a sale. ELN closed at $8.03 Monday. ELN February call option implied volatility is at 103, puts are at 112, above its 26-week average of 100 according to Track Data, suggesting larger price movement..

Biogen Idec (NASDAQ: BIIB) closed at $48.45 Monday. BIIB and ELN have a 50-50 stake in the multiple sclerosis drug Tysabri. ELN said it is initiating a strategic review which could result in a minority investment, a strategic alliance, a merger or a sale. BIIB February option implied volatility of 56 is near its 26-week average according to Track Data, suggesting non-directional price movement.

Crucell NV (NASDAQ: CRXL), a biopharmaceutical company, and Wyeth (NYSE: WYE) confirmed on January 7 the two firms are in discussion to combine. CRXL closed at $22.63 Monday. CRXL February option implied volatility of 58 is near its 26-week average of 61, according to Track Data, suggesting non-directional price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Options Update: Elan (ELN) volatility up into strategic review originally appeared on BloggingStocks on Tue, 13 Jan 2009 08:38:00 EST. Please see our terms for use of feeds.

It's been a tough year for many industries -- there's no denying it. Retailers of all stripes, oil companies, construction firms, financials, basic materials companies -- you name it, it's down.

So, are there any safe havens?

Historically, in times of economic uncertainty the pharmaceutical industry, along with consumer staples, is often the "go to" place where, at a minimum, you can count on a nice dividend yield to shield your portfolio from gigantic losses. Not anymore.

In this downturn even stalwarts such as Merck (NYSE: MRK) and Pfizer (NYSE: PFE) trade near their multi-year lows, despite offering generous yields.

What about biotechs? That sector has performed much better.

However, one of my favorite biotech names, Elan (NYSE: ELN), is struggling.

At the start of the year, ELN was looking strong. Its stock was up by 50% by mid-summer. Since then shares have collapsed and now trade in the mid-single digits.

I profiled the company on July 2, with one caveat: If late-stage testing of a new Alzheimer's drug called bapineuzumab doesn't go as planned, then ELN will trade lower.

About a month later, the company announced that the results of a Phase II clinical study showed the drug does safely treat the symptoms of Alzheimer's disease, but the results were not statistically significant, and the 234-person Phase II study would have to be broadened to a much larger Phase III study to be considered for FDA approval.

The shares fell 17% on the announcement, but that was just the start. As is often the case, when it rains, it pours.

Continue reading Biotech no longer a safe haven: Elan (ELN) falls on hard times

Biotech no longer a safe haven: Elan (ELN) falls on hard times originally appeared on BloggingStocks on Fri, 12 Dec 2008 15:01:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Merriman upgraded shares of Netezza (NYSE: NZ) to Buy from Neutral following the company's solid Q2 results as they believe it is well-positioned for strong operating results heading into 2H09.
  
• JP Morgan raised Cabot (NYS: CBT) to Overweight from Neutral. The firm expects 2009 to be a better year given lower raw material costs and higher contract prices.
  
• JP Morgan also upgraded Royal Ahold (OTC: AHONY) to Overweight from Neutral on valuation.
  
• Liberty International (OTC: LBYIY) was upgraded to Hold from Sell at Deutsche Bank.
  
• BMO Capital upgraded Royal Bank (NYSE: RY) to Market Perform from Underperform and Bank of Montreal (NYSE: BMO) to Outperform from Market Perform.

• Jefferies downgraded shares of Constellation Energy (NYSE: CEG) to Underperform on Hold on concerns the company will come under increasing pressure to issue equity. The firm lowered its target to $60 from $71.
• Thomas Weisel downgraded Williams-Sonoma (NYSE: WSM) to Market Weight from Overweight citing continued macro pressures.
  
• Wachovia has concerns that Kayne Anderson's (NYSE: KED) book value will be pressured by its investment in ProPetro Services, trading losses associated with SemGroup, and negative developments at Quest Midstream. The firm cut shares of Kayne to Market Perform from Outperform.
• Energy Conversion (NASDAQ: ENER) was downgraded to Neutral from Buy at Piper.
  
• Deutsche Bank cut International Paper (NYSE: IP) and Domtar (NYSE: UFS) to Hold from Buy.
  
• H&E Equipment (NASDAQ: HEES) was lowered at Credit Suisse to Neutral from Outperform.

• Morgan Stanley yesterday initiated Elan Corp (NYSE: ELN) with an Overweight rating. The firm sees a low-probability of a Tysabri withdrawal.
  
• ThinkPanmure views On Semiconductor (NASDAQ: ONNN) as a nice turnaround story with opportunities for shares gains in notebooks and consumer gaming platforms. Shares were initiated with a Buy rating and $14 target.
• Petrohawk Energy (NYSE: HK) was assumed with an Outperform rating at Morgan Keegan.
  
• Regency Energy (NASDAQ: RGNC) was initiated at Merrill Lynch with a Neutral rating.

Analyst calls: NZ, CEG, WSM, CBT, ELN ... originally appeared on BloggingStocks on Fri, 29 Aug 2008 11:42:00 EST. Please see our terms for use of feeds.

"If you want to buy a great company dirt cheap, think Biogen Idec (NASDAQ: BIIB)," says biotech expert Michael Shulman. Here's an update from ChangeWave Biotech Investor.

"Biogen recently got hammered on 'bad' news that wasn't actually so bad. BIIB and partner Elan (NYSE: ELN) reported that two MS patients, out of 31,800 currently receiving Tysabri, developed a rare brain malady called PML.

"It's important to note, here, that the two companies had predicted that one in 1000 cases could develop PML and the FDA let the drug come to market with this understanding with a strong set of patient warnings and physician follow up.

"Tysabri has succeeded in the marketplace because it is a superior treatment for MS -- and the patients who use it agree, despite its high cost of $30,000 per year. I expect only a very small drop off in market acceptance for Tysabri and when it becomes apparent the drug is still desired by patients and doctors, the stock should rebound significantly.

"BIIB is still targeting 100,000 patients by 2010 and that would translate into $1 billion per quarter in sales.The two cases of PML cut the stock by almost 30% -- and that's ridiculous. It's simply too big a move for a cash-rich, risk-free company with several major drugs -- especially Rituxan which is taking more market share every quarter.

"Biogen Idec also has the ability to add new products through licensing or direct acquisition, and I expect it to do so in the coming quarters. This temporary downturn is a godsend for investors! BIIB is now selling well below the valuations of other large-cap, double-digit biotech growers. Take advantage of this mistake before the Street wakes up."

Steven Halpern's TheStockAdvisors.com offers a daily look at the latest market commentary and favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.

Biogen (BIIB): A 'dirt cheap' biotech bet originally appeared on BloggingStocks on Mon, 25 Aug 2008 11:16:00 EST. Please see our terms for use of feeds.

Biogen (NASDAQ: BIIB) was trading at $54.71 in pre-open trading, below its close of $69.76 Thursda. BIIB and Elan (NYSE: ELN) announced their multiple sclerosis treatment Tysabri, was linked to brain infection. BIIB August option implied volatility was at 42, September at 39; near its 26-week average of 39 according to Track Data, suggesting non-directional price movement.

ELN was trading at $10.78 in pre-open trading, below its close of $20.05. ELN August option implied volatility was at 65, October at 58; below its 26-week average of 70, suggesting decreasing price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Option Update: Biogen and Elan trading lower on Tysabri link to brain infection originally appeared on BloggingStocks on Fri, 01 Aug 2008 10:10:00 EST. Please see our terms for use of feeds.

Crocs (NASDAQ: CROX) is trading at $5.06 late this morning, well below its close of $8.94. CROX lowered Q2 and 2008 financial guidance. Robert Baird Co lowered its rating to Neutral from Outperform. CROX over all option implied volatility of 91 is above its 26-week average of 84 according to Track Data, suggesting larger price movement.

Mechel Steel (NYSE: MTL) closed at $22.84, and is trading up this morning at $26.40. MTL sold off 38% on July 24 after Russian Prime Minister Vladimir Putin ordered antitrust authorities to investigate selling prices at steel and coal group MTL. MTL August option implied volatility is at 162, October is at 105, above its 26-week average of 66 according to Track Data, suggesting larger price fluctuations.

Elan Corp (NYSE: ELN) closed at $32.34 and, as of 11:15 Friday morning, is trading at $33.43. ELN's & WYE's Bapineuzumab (Alzheimer's treatment) Phase 2 trial results will be presented at the International Conference on Alzheimer's Disease on July 29. ELN August option implied volatility is at 97, October is at 70; above its 26-week average of 69 according to Track Data, suggesting larger price fluctuations.

Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Options Update: Crocs (CROX), Mechel Steel (MTL), Elan Corp (ELN) originally appeared on BloggingStocks on Fri, 25 Jul 2008 12:00:00 EST. Please see our terms for use of feeds.

Elan Corp (NYSE: ELN) is recently trading at $28.41 in pre-open trading, above its close of $27.11 Monday.

ELN and Wyeth (NYSE: WYE)'s Bapineuzumab (Alzheimer's treatment) Phase 2 trial results were positive. Detailed results of the trial will be presented at the International Conference on Alzheimer's Disease on July 29, 2008.

ELN July option implied volatility is at 107, October is at 82; above its 26-week average of 68 according to Track Data, suggesting larger price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Option Update: Elan Corp volatility up into positive Phase 2 Alzheimer's data originally appeared on BloggingStocks on Tue, 17 Jun 2008 09:18:00 EST. Please see our terms for use of feeds.